Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2006-11-30
2008-11-25
Eyler, Yvonne (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C514S649000
Reexamination Certificate
active
07456317
ABSTRACT:
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.
REFERENCES:
patent: 4535186 (1985-08-01), Husbands
patent: 5916923 (1999-06-01), Rudolph
patent: 6274171 (2001-08-01), Sherman
patent: 6403120 (2002-06-01), Sherman
patent: 6419958 (2002-07-01), Sherman
patent: 6440457 (2002-08-01), Edgren
patent: 6444708 (2002-09-01), Rudolph
patent: 6579899 (2003-06-01), Wurtman
patent: 2002/0094995 (2002-07-01), Foster
patent: 2005/0118264 (2005-06-01), Sela
patent: 2005/0181071 (2005-08-01), Binder
patent: 0112669 (1984-07-01), None
patent: 0654264 (1995-05-01), None
Bassapa et al., “Simple and efficient method for the synthesis of 1-[2-dimethylamino-1(4-methoxy-phenyl)-ethyl]-cyclohexanol hydrochloride: (±venlafaxine racemic mixtures,” Biorg. Med. Chem. Lett. 14:3279-3281 (2004).
Browne, “Isotope effect: implications for pharmaceutical investigations,” Pharmacochem. Library 26:13-18 (1997).
Chavan et al., “An efficient and green protocol for the preparation of cycloalkanols: a practical synthesis of venlafaxine,” Tetrahedron Lett. 45:7291-7295 (2004).
Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984).
Kushner, “Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds,” Can. J. Physiol. Pharmacol. 77:79-88 (1999).
Lessard et al., “Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans,” Pharmacogenetics 9(4):435-443 (1999).
Morton et al., “Venlafaxine: a structurally unique andnovel antidepressant,” Annals of Pharmacotherapy 29(4):387-395 (1995).
Pohl, “Determination of Toxic Pathways of Metabolism by Deuterium Substitution,” Drug Met. Rev. 15(7):1335-1351 (1985) (vol. Date 1984).
Reis et al., “Therapeutic Drug Monitoring of Racemic Venlafaxine and Its Main Metabolites in an Everyday Clinical Setting,” Therapeut. Drug Monitoring 24:545-553 (2002).
Yardley, J.P. et al., “2-phenyl-2-(1-hydroxycycloalkyl)ethylamin E derivatives: synthesis and antidepressant activity,” J. Med. Chem. 33:2899-2905 (1990).
PCT/US2006/045673 Search Report dated Mar. 6, 2007.
Gant Thomas G.
Sarshar Sepehr
Auspex Pharmaceuticals
Bennettt Dennis A
Cho Jennifer Y
Eyler Yvonne
LandOfFree
Substituted phenethylamines with serotoninergic and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted phenethylamines with serotoninergic and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted phenethylamines with serotoninergic and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4050009